Abstract
We present a case report of a patient with refractory eosinophilic asthma and nasal polyposis, in whom even with complex antiasthmatic treatment (step 5 according to Global Initiative for Asthma [GINA]) and oral corticosteroids, control of asthma symptoms could not be achieved. Clinical improvement did not occur until the administration of mepolizumab (Nucala), which clearly improved nasal discomfort.
With the remission of eosinophilic inflammation, we were able to gradually discontinue oral corticosteroids without relapse, and there was a reduction in the frequency of infectious rhinosinusitis and antibiotic treatment. The patient was offered a home self-administration of Nucala, which he handled well.
The asthma condition is now under long-term control. Biological treatment protected the patient from the disability pension, which his general practitioner and the patient himself were already considering.